Skip to main content

ANTENATAL DIAGNOSIS

Rh-disease is usually diagnosed during the routine prenatal screening. Predicting the fetal RhD status by non-invasive antenatal screening for the fetal RhD gene (RHD) can guide targeted use of antenatal anti-D prophylaxis.

What is HDFN in pregnancy?

Every woman in pregnancy should be tested for blood grouping determination and antibody screening to identify the Rh status and the presence of an immunization that posese the fetus at risk of hemolytic disease of fetus and newborn (HFDN) also known as erythroblastosis fetalis.

According to the American Academy of Pediatrics (AAP), “if a mother has not had prenatal blood grouping or is Rh- negative, a direct antibody test (or Coombs’ test), blood type, and an Rh (D) type on the infant’s (cord) blood are strongly recommended.”

Blood group and detection of irregular RBC antibodies checked at week 28th of pregnancy. The Rh and ABO statuses of the father of the fetus of a Rh-negative pregnant woman should be determined. If he is heterozygous, the risk of Rh immunization is halved. If the ABO and Rh genotype of the father are known, the risk of Rh immunization can be estimated.

It is important to retest regularly a Rh-negative pregnant woman who has a Rh-positive mate. Further testing should be carried out at weeks 18 to 20 of pregnancy and every 4 weeks thereafter considering that an initial immune response rarely occurs before the week 20 of gestation.

What are clinically significant red cell alloantibodies?

When the presence or development of red cell alloantibodies is not detected during pregnancy, the only, nonspecific, and unpredictable clinical features of HDFN during pregnancy are a decrease of fetal movements or sudden fetal death. 

When the presence of maternal anti-Rh antibodies is identified by screening, the pregnant woman must be monitored by repeated laboratory tests (antibody titers, antibody quantitation, antibody-dependent cellular cytotoxicity or ADCC). If these serum exams are above a certain cut-off level, it is necessary to carry out clinical investigations in specialized centers such as Echo-Doppler sonography to timely detect severe HDFN requiring fetal therapy or delivery with neonatal treatment. 

Thus, a screening program aims to identify those pregnancies in which intrauterine treatment of the fetus is needed and/or delivery should be induced to lower the risk of development of severe hemolytic disease. Without a screening program, treatment may be delayed.

What laboratory tests are involved in diagnosis of HDFN during pregnancy?

Since the fetus can become severely anemic from the 16th week of gestation onwards, non-invasive fetal blood group typing with cell-free fetal (cff) DNA from maternal plasma should be performed before 14–15 weeks for the screening of non-immunized D-negative women. 

Because cffDNA represents only a fraction of the total cell-free DNA in the maternal plasma, highly efficient DNA extraction and sensitive detection technology, currently with quantitative PCR, is required. 

Other methods applied to fetal RHD typing involve single-base extension, followed by demonstration of the specific products by GeneScan or mass spectrometer.

Recently, a chip-based digital PCR for fetal blood group typing has been described. This method is called droplet digital PCR (ddPCR).  In a ddPCR each droplet contains only a single copy of the maternal or fetal gene, and the presence of a fetal copy will therefore always result in a strongly positive signal that can easily be discriminated from droplets containing maternal DNA copies. 

Confirming the presence of fetal DNA with other paternally inherited DNA sequences (e.g. SRY) or a universal fetal DNA marker (e.g. methylated RASSF1a) is used by some laboratories to report conclusive results in one single assay. It can be concluded that non-invasive fetal genotyping can reliably be used to target laboratory and clinical monitoring to cases at risk for the development of severe HDFN. 

Degree of severity of hemolytic disease

In immunized Rh-negative women it is of utmost importance determine the degree of severity of erythroblastosis (if any) in the fetus. 

Six parameters can help to assess the degree of severity of hemolytic disease: 

1) history of preceding disease

2) maternal antibody titers 

3) cell-mediated maternal antibody functional assays 

4) amniotic fluid spectrophotometric measurements 

5) ultrasonographic assessment

6) direct fetal blood sampling. 

 

The definition of severity is as follows:

  • ‘Very severe HDFN’ refers to cases of intrauterine death and cases treated by intrauterine transfusions (IUTs) and/or exchange transfusion (ET) after birth.
  • ‘Severe HDFN’ also includes cases treated with top-up transfusions and cases in which preterm induction of labor is needed.
  • A ‘mild course’ is defined as cases without a need of pre- term induction of labor and in whom treatment with phototherapy suffices. 

Hazards of amniocentesis and induction of early delivery

It must be kept in mind that owing to the always present risk of fetomaternal hemorrhage (FMH), with consequent increasing antibody titers and increasing severity of hemolysis, amniocentesis should be carried out only after careful ultrasound placental localization. Amniocentesis carried out without ultrasound guidance is associated with a 10% – 11% risk of FMH and increased severity of erythroblastosis. However, even if ultrasound-guided, amniocentesis, being an invasive maneuver, can determine FMH. Thus, it should be undertaken only if the history or antibody titer indicates that the fetus is at risk of developing hydrops and dying.  Irrespective of antibody titer, amniocentesis should be undertaken at week 18 to 19 of gestation in case of history of previous stillbirth or if the previous newborn required ET after birth. In the absence of such history, amniocentesis should be performed only if there is an antibody titer indicating a consistent risk of hydrops.  

Only the fetus who will be hydropic before the week 34 of gestation should undergo fetal blood transfusions, and only these fetuses and those who will otherwise become hydropic between weeks 34 of gestation and term should be exposed to the hazards of induced early delivery. The risk of death linked to fetal transfusion trauma (intraperitoneal) is 10 – 15% at weeks 22 to 23 of a pregnancy and falls to 3- 5% after week 28. In the premature erythroblastosis infant with a severe disease, the risk of death is still nowadays significant at week 32 of gestation.

Disease model maternal alloimmunization leading to hemolytic disease of the fetus and newborn and laboratory testing and eventual clinical testing to discriminate high-risk cases. Modified by Haas M et al, 2015.

*If non-invasive fetal antigen typing is not available, pregnancies should be monitored as if the fetus is antigen positive when the biological father is homozygous or heterozygous positive for the respective antigen. Pregnancies can be monitored as if the fetus is antigen negative upon a negative non-invasive fetal antigen typing result, or when the biological father is typed with certainty as homozygous negative for the respective antigen